Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Autolus Therapeutics announced its operational and financial results for the first quarter ended March 31, 2026.
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "IgG4-Related Disease Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
-
Dublin, April 22, 2026 (GLOBE NEWSWIRE) -- The "Sjogren's Syndrome Market - A Global and Regional Analysis: Focus on Symptoms, Type, Route of Administration, End Users, and Region, 2025-2035" report...
-
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
-
Boehringer and Sitryx Therapeutics partner to advance autoimmune and inflammatory disease research for more personalized, targeted, data driven treatment.
-
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...
-
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...
-
Boehringer has licensed CDR111 from CDR-Life, an antibody-based trispecific M-gager® for autoimmune diseases.
-
Boehringer has licensed a small molecule program from Kyowa Kirin focused on developing potential treatments for autoimmune diseases.
-
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...